人表皮生长因子受体酶联免疫试剂盒描述：

       The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor (EGF) family of extracellular protein ligands. It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR exists on the cell surface and is activated by the binding of its specific ligands, including EGF and transforming growth factor a (TGFa). EGFR and its ligands are cell signaling molecules involved in diverse cellular functions, including cell proliferation, differentiation, motility, and survival as well as in tissue development. Mutations that lead to EGFR overexpression or overactivity have been associated with a number of cancers, including lung cancer and glioblastoma multiforme. In the latter case, a more or less specific mutation of EGFR, EGFRvIII, is often observed.

       ScienCell's human EGFR ELISA Kit is based on standard sandwich enzyme-linked immune-sorbent assay technology. Human EGFR specific-polyclonal antibodies are pre-coated onto 8 x 12 divisible strips. The human specific detection polyclonal antibodies are biotinylated. The test samples and biotinylated detection antibodies are subsequently added to the wells and then washed with PBS or TBS buffer.Avidin-Biotin-Peroxidase Complex is added, and unbound conjugates are washed away with PBS or TBS buffer. HRP substrate TMB is used to visualize HRP enzymatic reaction. TMB is catalyzed by HRP to produce a blue color product that changes into yellow after adding acidic stop solution. The intensity of yellow is proportional to the amount of human EGFR that is captured in strips.

产品使用说明：仅供科研研究使用。

       2. Wang, K.; Yamamoto, H.; Chin, J. R.; Werb, Z.; Vu, T. H.:Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem. 279: 53848-53856, 2004.

       3. Kuan CT, Wikstrand CJ, Bigner DD (June 2001). "EGF mutant receptor vIII as a molecular target in cancer therapy". Endocr. Relat. Cancer 8 (2): 83-96.